NR3C2 and atrial fibrillation: A meta-analysis by Neefs et al. explored the impact of mineralocorticoid receptor antagonists (MRAs) and revealed a 52% reduction in new-onset AF risk (OR 0.52, p < 0.001) and a 57.9% reduction in AF recurrence (OR 0.37, p < 0.001).